#10: Novel anticoagulants in AF: An overview of the latest data with Dr Robert McBane

Summary: The past year has brought an embarrassment of riches in the realm of anticoagulation for patients with atrial fibrillation, as dabigatran, rivaroxaban, and apixaban vie to compete with warfarin. Dr Robert McBane reviews the most recent data with Dr Bernard Gersh, assessing whether one agent has "an edge" over the others and reviewing the appropriate patient set for the novel agents and warfarin.